Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance
M Bhardwaj, MN Chiu… - Cutaneous and ocular …, 2022 - Taylor & Francis
Introduction The therapeutic use of humanised monoclonal programmed cell death 1 (PD-
1)(pembrolizumab, and nivolumab) and programmed cell death ligand-1 (PD …
1)(pembrolizumab, and nivolumab) and programmed cell death ligand-1 (PD …
Clinical features of dermatomyositis patients with anti-TIF1 antibodies: a case based comprehensive review
OC Kilinc, S Ugurlu - Autoimmunity Reviews, 2023 - Elsevier
Background and objectives Dermatomyositis is chronic autoimmune disease primarily
affecting skin and muscles. Antibodies are key players of pathogenesis and are in strong …
affecting skin and muscles. Antibodies are key players of pathogenesis and are in strong …
Paraneoplastic dermatomyositis associated with urothelial cancer: report of a case and systematic review of the literature
J Sabaté-Ortega, E Bujons-Buscarons… - Frontiers in …, 2023 - frontiersin.org
Background The idiopathic inflammatory myopathies (IIM) are a collection of autoimmune
diseases that have a substantial impact on the entire body and include conditions such as …
diseases that have a substantial impact on the entire body and include conditions such as …
Anti-transcription intermediary factor 1 gamma (TIF1γ) antibody-positive dermatomyositis associated with ascending colon cancer: a case report and review of the …
R Ono, T Kumagae, M Igasaki, T Murata… - Journal of Medical Case …, 2021 - Springer
Background Anti-transcriptional intermediary factor 1 gamma (TIF1γ) antibody is a marker for
predicting cancer association in patients with dermatomyositis (DM). The overall survival …
predicting cancer association in patients with dermatomyositis (DM). The overall survival …
Adverse Cutaneous Outbreaks by programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) immune checkpoint inhibitors: A Review.
M Bhardwaj, MN Chiu, S Sah - Authorea Preprints, 2024 - advance.sagepub.com
The therapeutic use of humanized monoclonal anti-programmed cell death 1 (PD-
1)(pembrolizumab, and nivolumab) and anti-programmed cell death ligand1 (PD …
1)(pembrolizumab, and nivolumab) and anti-programmed cell death ligand1 (PD …